Literature DB >> 9093586

Dunnigan-Kobberling syndrome: an autosomal dominant form of partial lipodystrophy.

S N Jackson1, T A Howlett, P G McNally, S O'Rahilly, R C Trembath.   

Abstract

Dunnigan-Kobberling syndrome is a form of partial lipodystrophy characterized by sparing of the face. Despite descriptions of six families since 1974, details of total body adipose tissue distribution and studies of carbohydrate and fat metabolism are lacking. The mode of inheritance also remains unclear, with most authors favouring an X-linked dominant transmission lethal in the hemizygous male. We examined 23 members of a family, of whom at least eight had partial lipodystrophy. Auxological evaluation and cross-sectional imaging showed absence of subcutaneous fat, presence of adipose tissue inside the body cavities, and skeletal muscle hypertrophy. Biochemical evaluation identified insulin resistance but revealed inadequate suppression of non-esterified fatty acids. In this family, male-to-male transmission supports an autosomal dominant mode of inheritance for Dunnigan-Kobberling syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093586     DOI: 10.1093/qjmed/90.1.27

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  10 in total

1.  A defect in the regional deposition of adipose tissue (partial lipodystrophy) is encoded by a gene at chromosome 1q.

Authors:  S N Jackson; J Pinkney; A Bargiotta; C D Veal; T A Howlett; P G McNally; R Corral; A Johnson; R C Trembath
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 2.  Genetics of Lipodystrophy.

Authors:  Marissa Lightbourne; Rebecca J Brown
Journal:  Endocrinol Metab Clin North Am       Date:  2017-02-22       Impact factor: 4.741

3.  Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome.

Authors:  Cristina Guillín-Amarelle; Sofía Sánchez-Iglesias; Ana Castro-Pais; Leticia Rodriguez-Cañete; Lucía Ordóñez-Mayán; Marcos Pazos; Blanca González-Méndez; Silvia Rodríguez-García; Felipe F Casanueva; Ana Fernández-Marmiesse; David Araújo-Vilar
Journal:  Endocrine       Date:  2016-07-30       Impact factor: 3.633

Review 4.  Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

5.  Digenic Variants in the FGF21 Signaling Pathway Associated with Severe Insulin Resistance and Pseudoacromegaly.

Authors:  Stephen I Stone; Daniel J Wegner; Jennifer A Wambach; F Sessions Cole; Fumihiko Urano; David M Ornitz
Journal:  J Endocr Soc       Date:  2020-09-22

6.  A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease.

Authors:  Hitomi Imachi; Koji Murao; Shouji Ohtsuka; Mako Fujiwara; Tomie Muraoka; Hitoshi Hosokawa; Toshihiko Ishida
Journal:  Endocrine       Date:  2008-11-15       Impact factor: 3.633

7.  Body fat distribution in women with familial partial lipodystrophy caused by mutation in the lamin A/C gene.

Authors:  Luciana Z Monteiro; Maria C Foss-Freitas; Renan M Júnior Montenegro; Milton C Foss
Journal:  Indian J Endocrinol Metab       Date:  2012-01

Review 8.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

9.  Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes.

Authors:  Camille Vatier; Dina Kalbasi; Marie-Christine Vantyghem; Olivier Lascols; Isabelle Jéru; Anne Daguenel; Jean-François Gautier; Marion Buyse; Corinne Vigouroux
Journal:  Orphanet J Rare Dis       Date:  2019-07-12       Impact factor: 4.123

10.  Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene.

Authors:  D B Savage; M A Soos; A Powlson; S O'Rahilly; I McFarlane; D J Halsall; I Barroso; E L Thomas; J D Bell; I Scobie; P E Belchetz; W F Kelly; A J Schafer
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.